822 related articles for article (PubMed ID: 17363526)
1. Clinical implications of fibroblast activation protein in patients with colon cancer.
Henry LR; Lee HO; Lee JS; Klein-Szanto A; Watts P; Ross EA; Chen WT; Cheng JD
Clin Cancer Res; 2007 Mar; 13(6):1736-41. PubMed ID: 17363526
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.
Cohen SJ; Alpaugh RK; Palazzo I; Meropol NJ; Rogatko A; Xu Z; Hoffman JP; Weiner LM; Cheng JD
Pancreas; 2008 Aug; 37(2):154-8. PubMed ID: 18665076
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
4. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model.
Cheng JD; Dunbrack RL; Valianou M; Rogatko A; Alpaugh RK; Weiner LM
Cancer Res; 2002 Aug; 62(16):4767-72. PubMed ID: 12183436
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival.
Ge Y; Zhan F; Barlogie B; Epstein J; Shaughnessy J; Yaccoby S
Br J Haematol; 2006 Apr; 133(1):83-92. PubMed ID: 16512833
[TBL] [Abstract][Full Text] [Related]
6. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.
Ladner RD; Lynch FJ; Groshen S; Xiong YP; Sherrod A; Caradonna SJ; Stoehlmacher J; Lenz HJ
Cancer Res; 2000 Jul; 60(13):3493-503. PubMed ID: 10910061
[TBL] [Abstract][Full Text] [Related]
7. Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma.
Liu W; Liu Y; Zhu J; Wright E; Ding I; Rodgers GP
Clin Cancer Res; 2008 Feb; 14(4):1041-9. PubMed ID: 18281536
[TBL] [Abstract][Full Text] [Related]
8. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
[TBL] [Abstract][Full Text] [Related]
9. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
12. Expression of stromal cell markers in distinct compartments of human skin cancers.
Huber MA; Kraut N; Schweifer N; Dolznig H; Peter RU; Schubert RD; Scharffetter-Kochanek K; Pehamberger H; Garin-Chesa P
J Cutan Pathol; 2006 Feb; 33(2):145-55. PubMed ID: 16420310
[TBL] [Abstract][Full Text] [Related]
13. Loss of KAI1 expression in the progression of colorectal cancer.
Lombardi DP; Geradts J; Foley JF; Chiao C; Lamb PW; Barrett JC
Cancer Res; 1999 Nov; 59(22):5724-31. PubMed ID: 10582691
[TBL] [Abstract][Full Text] [Related]
14. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
15. The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
Tsamandas AC; Kardamakis D; Ravazoula P; Zolota V; Salakou S; Tepetes K; Kalogeropoulou C; Tsota I; Kourelis T; Makatsoris T; Karavias D; Scopa CD; Bonikos DS; Kalofonos HP; Petsas T
Strahlenther Onkol; 2004 Apr; 180(4):201-8. PubMed ID: 15057430
[TBL] [Abstract][Full Text] [Related]
16. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer.
Engelhardt M; Drullinsky P; Guillem J; Moore MA
Clin Cancer Res; 1997 Nov; 3(11):1931-41. PubMed ID: 9815582
[TBL] [Abstract][Full Text] [Related]
17. Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: homology to Schistosoma mansoni amino acid permease and Caenorhabditis elegans gene products.
Wolf DA; Wang S; Panzica MA; Bassily NH; Thompson NL
Cancer Res; 1996 Nov; 56(21):5012-22. PubMed ID: 8895758
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Okugawa Y; Fujikawa H; Matsusita K; Kawamura M; Inoue Y; Miki C; Kusunoki M
Int J Oncol; 2011 Mar; 38(3):655-63. PubMed ID: 21240461
[TBL] [Abstract][Full Text] [Related]
19. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
[TBL] [Abstract][Full Text] [Related]
20. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Scott AM; Wiseman G; Welt S; Adjei A; Lee FT; Hopkins W; Divgi CR; Hanson LH; Mitchell P; Gansen DN; Larson SM; Ingle JN; Hoffman EW; Tanswell P; Ritter G; Cohen LS; Bette P; Arvay L; Amelsberg A; Vlock D; Rettig WJ; Old LJ
Clin Cancer Res; 2003 May; 9(5):1639-47. PubMed ID: 12738716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
